Alzheimer’s disease (AD) is a complex progressive neurodegenerative disease characterized by the accumulation of Aβ plaques and tau NFTs, which are considered to result in neuronal loss and cognitive decline. This slide deck discusses neurobiology and aetiology for AD and highlights topics as risk factors, pathopsysiological hypotheses, and the development and importance of biomarkers.

This slide deck has been developed by Joseph Therriault, PhD, McGill University, Montréal, Québec, Canada; and Professor Serge Gauthier, McGill University, Montréal, Québec, Canada, in collaboration with Cambridge Medical – A Prime Global agency.

Index for
slide deck

Introduction

Neurobiology and aetiology

Neurobiology and aetiology

file_download Download slide in HQ
Alzheimer’s disease research timeline

Alzheimer’s disease research timeline

Diagnosis of AD has developed from a pathological approach to a more clinical and exclusionary approach.1,3 NIA-AA Criteria published in 2011, combined with a clinical and biological approach developed by the International Working Group (IWG), allowed for the emergence of…

file_download Download slide in HQ
Alzheimer’s disease is not synonymous with dementia

Alzheimer’s disease is not synonymous with dementia

References on slide:
1.Alzheimer’s Disease International website. Dementia facts and figures. Available at: https://www.alzint.org/about/dementia-facts-figures/. Accessed 1 June 2023.

2.Alzheimer’s Association website. What is dementia? Available at: https://www.alz.org/al…

file_download Download slide in HQ
What is neurodegeneration?

What is neurodegeneration?

Aβ and tau pathology in AD results in neuroinflammation, mitochondrial dysfunction, metabolic dysregulation, and protein deficiency.1 The resulting neurotoxicity and disturbed neuroplasticity that occur lead to neurodegeneration.1 In vivo, neurodegeneration in AD is ident…

file_download Download slide in HQ

Risk factors

Risk factors

Risk factors

file_download Download slide in HQ
What factors are at play in Alzheimer’s disease?

What factors are at play in Alzheimer’s disease?

While the most prominent risk factor for AD is increasing age, the disease develops as a result of several risk factors that converge.2 Environmental factors such as traumatic brain injury, ischemia, hypoxia, neurotoxins, infections, lifestyle, metabolic parameters, and c…

file_download Download slide in HQ
Genetic risk factors

Genetic risk factors

The estimated heritability of AD is approximately 70%, and does not differ between sex.1,9 To date, 75 risk loci have been identified for AD and related dementias.8 Several studies in multiple ethnic groups have associated the APOE gene with familial-AD and sporadic late-…

file_download Download slide in HQ
Modifiable lifestyle factors and prevention strategies

Modifiable lifestyle factors and prevention strategies

AD has a long prodromal phase, during which early prevention is important to slow progression of the disease.1 Psychosocial factors such as educational attainment and bilingualism work to enhance cognitive activity, processing, and intellectual capacities.1,3 Regular soci…

file_download Download slide in HQ
Accumulation of dementia risk factors over time

Accumulation of dementia risk factors over time

Maintaining good physical health in individuals with dementia is important for cognition.1 In early life (i.e., <45 years), lack of education has been associated with an increased risk of dementia.1 In middle life (i.e., 45–65 years), and not necessarily in later life (i.…

file_download Download slide in HQ

Related content

Article cover image showing blood samples and a hand description Article
Fluid biomarkers in Alzheimer’s disease: from detecting the pathology to understanding when it causes symptoms

Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.

13.10.2026 Alzheimer’s Disease
image Image Diagram showing current and potential applications of blood-based biomarkers across the Alzheimer’s disease pathway
Current and potential applications for fluid biomarkers

Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.

13.10.2026 Alzheimer’s Disease
image Image Flowchart illustrating a plasma biomarker testing protocol for symptomatic Alzheimer’s disease
A two-step blood-based algorithm

Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.

13.10.2026 Alzheimer’s Disease